ReviewCurrent hypertension reports2020
Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
Review in Current hypertension reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Battle of the giants: KDIGO vs. Cochrane - who is the winner in the fight for blood pressure targets in chronic kidney disease?Jornal brasileiro de nefrologiaPooled it
- Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis.Frontiers in medicine · 2026Article
- Hypertension in chronic kidney disease: where do international guidelines converge and diverge?Clinical hypertension · 2026Review
- Efficacy and safety of finerenone in obesity-related glomerulopathy.Clinical kidney journal · 2025Article
- Resistant and Apparently Resistant Hypertension in Peritoneally Dialyzed Patients.Journal of clinical medicine · 2025Review
- Review
- Gender and race disparities in the prevalence of chronic kidney disease among individuals with hypertension in the United States, 2001-2016.Frontiers in endocrinology · 2024Article
- Causes of Chronic Kidney Disease and Their Associations with Cardiovascular Risk and Disease in a Sub-Saharan Low-Income Population.International journal of nephrology and renovascular disease · 2024Article
- Predicting chronic responses to calcium channel blockade with a virtual population of African Americans with hypertensive chronic kidney disease.Frontiers in systems biology · 2024Article
- Hypertension in chronic kidney disease-treatment standard 2023.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Review
- Antihypertensive effects of immunosuppressive therapy in autoimmune disease.Journal of human hypertension · 2023Article
- Efficacy of hemodialysis combined with hemofiltration in the treatment of uremia complicated with intractable hypertension.American journal of translational research · 2023Article
- Association of living alone and living alone time with hypertension among Chinese men aged 80 years and older: a cohort study.Frontiers in public health · 2023Article
- Potassium Homeostasis and WNK Kinases in the Regulation of the Sodium-Chloride Cotransporter: Hyperaldosteronism and Its Metabolic Consequences.Kidney360 · 2022Article
- Role of α1-blockers in the current management of hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2022Review
- Article
- Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease.Kidney international reports · 2021Review
- Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets.American journal of hypertension · 2021Article
- How Do I Manage Hypertension in Patients with Advanced Chronic Kidney Disease Not on Dialysis? Perspectives from Clinical Practice.Vascular health and risk management · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewTo explore the prevalence, treatment particularities, and research agenda in the management of resistant hypertension among patients with chronic kidney disease (CKD). RECENT
findingsThe prevalence of resistant hypertension is reported to be 2-3 times higher in patients with CKD than in the general hypertensive population. Based in part on the results of the PATHWAY-2 trial showing add-on spironolactone to be superior to placebo or active treatment with an α- or β-blocker in reducing BP, international guidelines recommend the use of spironolactone as fourth-line agent in pharmacotherapy of resistant hypertension. Despite the several-fold higher burden of resistant hypertension among patients with stage 3b-4 CKD, the use of spironolactone in this population has been restricted, mainly due to the risk of hyperkalemia. The recently reported AMBER trial showed that among patients with uncontrolled resistant hypertension and an estimated glomerular filtration rate of 25-45 ml/min/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.